MYC and diffuse large B-cell lymphoma: Based on our results, we believe that the finding of MYC amp alone on FISH should not be interpreted as a marker of aggressive disease and patients should continue to be treated with the standard of care first-line regimen as for DLBCL i.e., currently R-CHOP28.